David Morris, MD, FACS; John Phillips, MD; Jeremy McDuffie, MD; Katy Beckermann, MD, PhD; and Alan Tan, MD, explore the distinct roles of alpha and beta emitters in radiopharmaceutical therapy, the promise of triplet therapy, and the integration of precision medicine in the final segment of this roundtable series. They discuss the operational challenges and clinical considerations of radioligand therapies like lutetium-177 PSMA and radium, their impact on patient outcomes, and the potential to move these therapies earlier in the treatment paradigm. ...
mHSPC
Advertisement
Latest News
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.